Giuseppe Procopio
@g_procopio_
Medical Oncologist focused on #GU cancers @IstTumori @meeturoIT @ficog
ID: 1616437142934417409
20-01-2023 14:07:59
301 Tweet
323 Followers
292 Following
❇️ From #NOresponse to #NOrelapse AIOM Società Italiana di Urologia 🇮🇹 #RCC #AdjTherapy #DFS #OS Kidney Cancer IKCC Kidney Cancer 🧡💚
🌟 #MeetTheEditors Genitourinary Oncology Section of TJ, led by dr. Giuseppe Giuseppe Procopio , dr. Patrizia Patrizia Giannatempo and dr. Marcello Tucci, is focused on evaluation of articles on detection, diagnosis, prevention and treatment of genitourinary tumors, promoting studies
The online #FAD course (5 ECM credits) on "modern #multidisciplinary approach to #renal #cancer" promoted by Società Italiana di Urologia is online To register: 👉ecm.siu.it/front/single/2… 🎓Several experts from multiple specialties 🇮🇹 Italian language 📆Accessible until June 2026 📺Video
Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review. Doi: doi.org/10.1016/j.clgc… Anna Amela Valsecchi #meeturo #clinicalgenitourinarycancer
Even within the same country (Italy), use of off-label cancer drugs is subject to significant inter-hospital variability. This leads to potential disparities in patients' access to care. Have a look at the project by AIOM, just published on Tumori Journal: journals.sagepub.com/eprint/VXIKKBV…
Kudos to Elena Verzoni on a terrific talk on imaging in #kidneycancer & #bladdercancer at #ESMO25! A tough topic well encompassed in 20 min, with citations of the pivotal work in this space by @kidneycancerdoc.
Katie Coleman Elizabeth Plimack MD Cristiane D Bergerot, PhD, FASCO Nazli Dizman Bradley McGregor Giuseppe Procopio Benjamin L Maughan Salvatore La Rosa Giannicola Genovese MD, PhD Jason A. Mouabbi MD Linghua Wang, MD, PhD Omar Alhalabi, MD Luigi Perelli Rahul Sheth Chad Tang, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Qing Zhang Brittney Cotta, MD Dan George Daniel Heng Priya Rao, MD Ashish M. Kamat, MD, MBBS ROHIT MEHRA Eleonora Dondossola,PhD Daniel E. Frigo, Ph.D. Samson W. Fine, MD Katy Beckermann Shilpa Gupta Amanda Nizam, MD Ziad Bakouny, MD, MSc 5/5 Clinical evidence: Sacituzumab govitecan in 4 heavily pretreated RMC pts → 1 PR (~5.3 mo) + 2 SD; median PFS 2.9 mo. Early, small-n but proof that biology-guided targeting can bend the curve for RMC. Next: more RMC-specific trials based on these biological insights.